Validation of ctDNA Quality Control Materials Through a Precompetitive Collaboration of the Foundation for the National Institutes of Health | Zendy

P. Mickey Williams | Zendy; Thomas Forbes | Zendy; Steven P. Lund | Zendy; Kenneth D. Cole | Zendy; HuaJun He | Zendy; Chris Karlovich | Zendy; Cloud P. Paweletz | Zendy; Daniel Stetson | Zendy; Laura M. Yee | Zendy; Dana E. Connors | Zendy; Susan M. Keating | Zendy; Benoit Destenaves | Zendy; Megan H. Cleveland | Zendy; Christie J. Lau | Zendy; J. Carl Barrett | Zendy; Gary J. Kelloff | Zendy; Robert McCormack | Zendy

Open Access

Validation of ctDNA Quality Control Materials Through a Precompetitive Collaboration of the Foundation for the National Institutes of Health

Author(s) -

P. Mickey Williams,

Thomas Forbes,

Steven P. Lund,

Kenneth D. Cole,

HuaJun He,

Chris Karlovich,

Cloud P. Paweletz,

Daniel Stetson,

Laura M. Yee,

Dana E. Connors,

Susan M. Keating,

Benoit Destenaves,

Megan H. Cleveland,

Christie J. Lau,

J. Carl Barrett,

Gary J. Kelloff,

Robert McCormack

Publication year - 2021

Publication title -

jco precision oncology

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 2.405

H-Index - 22

ISSN - 2473-4284

DOI - 10.1200/po.20.00528

Subject(s) - indel , digital polymerase chain reaction , amplicon , computational biology , polymerase chain reaction , genetics , biology , single nucleotide polymorphism , gene , genotype

We report the results from a Foundation for the National Institutes of Health Biomarkers Consortium project to address the absence of well-validated quality control materials (QCMs) for circulating tumor DNA (ctDNA) testing. This absence is considered a cause of variance and inconsistencies in translating ctDNA results into clinical actions.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research